These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

480 related items for PubMed ID: 24754246

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
    Wang X, Wong J, Sevinsky CJ, Kokabee L, Khan F, Sun Y, Conklin DS.
    Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
    Huang W, Wu QD, Zhang M, Kong YL, Cao PR, Zheng W, Xu JH, Ye M.
    Cancer Lett; 2015 Jan 28; 356(2 Pt B):862-71. PubMed ID: 25449780
    [Abstract] [Full Text] [Related]

  • 10. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.
    O'Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, Duffy MJ, Crown J, O'Donovan N, Slamon DJ.
    Mol Cancer Ther; 2010 Jun 28; 9(6):1489-502. PubMed ID: 20501798
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G, Capellero S, Cavalloni G, Zaccarello G, Petrelli A, Migliardi G, Milani A, Peraldo-Neia C, Gammaitoni L, Sapino A, Pecchioni C, Moggio A, Giordano S, Aglietta M, Montemurro F.
    Breast Cancer Res Treat; 2011 Nov 28; 130(1):29-40. PubMed ID: 21153051
    [Abstract] [Full Text] [Related]

  • 15. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
    Elster N, Cremona M, Morgan C, Toomey S, Carr A, O'Grady A, Hennessy BT, Eustace AJ.
    Breast Cancer Res Treat; 2015 Jan 28; 149(2):373-83. PubMed ID: 25528022
    [Abstract] [Full Text] [Related]

  • 16. Human Epidermal Growth Factor Receptor 2 (HER2) Impedes MLK3 Kinase Activity to Support Breast Cancer Cell Survival.
    Das S, Sondarva G, Viswakarma N, Nair RS, Osipo C, Tzivion G, Rana B, Rana A.
    J Biol Chem; 2015 Aug 28; 290(35):21705-12. PubMed ID: 26152725
    [Abstract] [Full Text] [Related]

  • 17. JARID2 activation by NFYA promotes stemness of triple-negative breast cancer cells through the PI3K/AKT pathway.
    Li J, Zhang X, Liu X, Ma X, Wang Y, Liu Y.
    Expert Rev Anticancer Ther; 2024 Oct 28; 24(10):1029-1040. PubMed ID: 39254227
    [Abstract] [Full Text] [Related]

  • 18. RON confers lapatinib resistance in HER2-positive breast cancer cells.
    Wang Q, Quan H, Zhao J, Xie C, Wang L, Lou L.
    Cancer Lett; 2013 Oct 28; 340(1):43-50. PubMed ID: 23811285
    [Abstract] [Full Text] [Related]

  • 19. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
    Park SH, Ito K, Olcott W, Katsyv I, Halstead-Nussloch G, Irie HY.
    Breast Cancer Res; 2015 Jun 19; 17(1):86. PubMed ID: 26084280
    [Abstract] [Full Text] [Related]

  • 20. HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells.
    Duru N, Fan M, Candas D, Menaa C, Liu HC, Nantajit D, Wen Y, Xiao K, Eldridge A, Chromy BA, Li S, Spitz DR, Lam KS, Wicha MS, Li JJ.
    Clin Cancer Res; 2012 Dec 15; 18(24):6634-47. PubMed ID: 23091114
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.